The full results, presented at the annual American Society of Clinical Oncology meeting in Chicago and published in the Journal of Clinical Oncology, show that Trodelvy reduced the risk of death by 16%, with similar improvement for harder-to-treat squamous and non-squamous types of NSCLC.
Tag Archive for: Gilead
“Gilead delivered another strong quarter of revenue growth … in our base business driven by HIV, Oncology and Liver Diseases,” CEO Daniel O’Day said in a statement, adding that the pharma is looking forward to a year of promising pipeline updates, particularly regarding its long-acting HIV and cancer programs.
The financing was secured from life sciences investment company Abingworth and will help Gilead run “select clinical studies” of Trodelvy.
Backed by Gilead Sciences (GILD.O) and Bain Capital Life Sciences Opportunities, Kyverna increased the pricing of its IPO and now plans to raise up to $304.5 million by selling 14.5 million shares priced between $20 and $21 apiece.
The company announced today that the trial failed to show that it significantly improved survival for previously treated patients with advanced non-small cell lung cancer.
AstraZeneca said on Tuesday it will buy Gracell Biotechnologies for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world’s second-largest pharmaceuticals market.
In the third quarter, Gilead‘s growth in its HIV and oncology businesses was nearly completely offset by declining sales from its COVID-19 drug Veklury (remdesivir) and hepatitis C virus portfolio.
The first-in-class antibody-drug conjugate—in combination with Merck’s Keytruda—has shown promising results in a Phase II study of patients with metastatic non-small cell lung cancer.
Teva Pharmaceuticals on Monday announced that it reached a deferred prosecution agreement with the U.S. Department of Justice over its drug price-fixing case involving generic drugs.
The company said it now expects sales of Veklury, known generically as remdesivir, to total $1.7 billion this year, down from its previous estimate of around $2 billion.